CN105636438A - 一种包含ampk激活剂及血清素活性制剂之医药组合物及其用途 - Google Patents

一种包含ampk激活剂及血清素活性制剂之医药组合物及其用途 Download PDF

Info

Publication number
CN105636438A
CN105636438A CN201480028057.0A CN201480028057A CN105636438A CN 105636438 A CN105636438 A CN 105636438A CN 201480028057 A CN201480028057 A CN 201480028057A CN 105636438 A CN105636438 A CN 105636438A
Authority
CN
China
Prior art keywords
acetamide
piperidin
fluorobenzyl
ethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480028057.0A
Other languages
English (en)
Chinese (zh)
Inventor
陈建宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105636438(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CN105636438A publication Critical patent/CN105636438A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pregnancy & Childbirth (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
CN201480028057.0A 2013-03-15 2014-03-14 一种包含ampk激活剂及血清素活性制剂之医药组合物及其用途 Pending CN105636438A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361793407P 2013-03-15 2013-03-15
US61/793,407 2013-03-15
PCT/US2014/028413 WO2014144130A2 (en) 2013-03-15 2014-03-14 Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof

Publications (1)

Publication Number Publication Date
CN105636438A true CN105636438A (zh) 2016-06-01

Family

ID=51538303

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480028057.0A Pending CN105636438A (zh) 2013-03-15 2014-03-14 一种包含ampk激活剂及血清素活性制剂之医药组合物及其用途

Country Status (16)

Country Link
US (1) US20140350064A1 (https=)
EP (1) EP2983473A4 (https=)
JP (1) JP2016513734A (https=)
KR (1) KR20160005341A (https=)
CN (1) CN105636438A (https=)
AR (1) AR095631A1 (https=)
AU (1) AU2014227807B2 (https=)
BR (1) BR112015023922A2 (https=)
CA (1) CA2909633A1 (https=)
CL (1) CL2015002680A1 (https=)
HK (1) HK1222297A1 (https=)
IL (1) IL241587B (https=)
MX (1) MX2015012760A (https=)
RU (1) RU2015143438A (https=)
TW (1) TW201444552A (https=)
WO (1) WO2014144130A2 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108159044A (zh) * 2018-02-26 2018-06-15 华中科技大学 抗坏血酸与二甲双胍的复合制剂用于制备化疗药物的应用
CN109689678A (zh) * 2016-09-20 2019-04-26 B·B·金 用于脂联素受体的激动剂肽
CN109771424A (zh) * 2019-03-11 2019-05-21 马慧 一种防治老年ⅱ型糖尿病性骨质疏松症的药物组合物及其应用
CN109793727A (zh) * 2019-03-13 2019-05-24 湖北科技学院 一种有效抗恶性肿瘤的药物组合物及其应用
CN110559298A (zh) * 2019-10-28 2019-12-13 中国药科大学 一种天然化合物Egenine用于制备抗肾纤维化药物的用途
CN111960985A (zh) * 2018-08-08 2020-11-20 中国人民解放军总医院 抗肿瘤化合物
US12612363B2 (en) 2019-06-19 2026-04-28 GH Research Ireland Limited Recrystallisation of 5-methoxy-N,N-dimethyltryptamine(5-MeO-DMT)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180071269A1 (en) * 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
ES2567105B1 (es) * 2014-09-19 2017-02-10 Consejo Superior De Investigaciones Científicas (Csic) Derivados de indol para la prevención y/o tratamiento de diabetes ytrastornos metabólicos relacionados
WO2016126662A1 (en) * 2015-02-03 2016-08-11 Kardiatonos, Inc. Compounds for the prevention and treatment of vascular disease
WO2016200726A1 (en) * 2015-06-08 2016-12-15 Texas Tech University System Inhibitors of mci-1 as drugs to overcome resistance to braf inhibitors and mek inhibitors
WO2017018752A1 (ko) * 2015-07-29 2017-02-02 고려대학교 산학협력단 부스피론 유도체 및 이를 함유하는 약학 조성물
KR101663543B1 (ko) * 2015-07-29 2016-10-07 고려대학교 산학협력단 부스피론 유도체 및 이를 함유하는 약학 조성물
US10357466B2 (en) * 2015-08-01 2019-07-23 Stephen J. Petti Compositions and methods for combination pharmacological treatments to induce a prolonged, mild decrease in core body temperature
CN105541665A (zh) * 2016-02-18 2016-05-04 江苏大学 一种抗肿瘤药物化合物及制备方法和应用
US11040935B2 (en) 2016-10-05 2021-06-22 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule AMPK activators
WO2018115010A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
ES2769286T3 (es) 2016-12-20 2020-06-25 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina
ES2881783T3 (es) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
CN107252425A (zh) * 2017-07-12 2017-10-17 上海华堇生物技术有限责任公司 去氢延胡索素的药物用途
MA50786A (fr) * 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
US11103465B2 (en) 2017-11-22 2021-08-31 Ted's Brain Science, Inc. Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof
US11208475B1 (en) * 2018-01-30 2021-12-28 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CA3101420A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
EP4027987A4 (en) 2019-09-10 2023-11-29 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods and materials for increasing level of phosphorylated ampk protein
AU2020372682A1 (en) * 2019-10-31 2022-06-09 Jd Bioscience Inc. Tricyclic compound and pharmaceutical use thereof
KR20240096817A (ko) 2020-05-19 2024-06-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법
CN114728933B (zh) * 2020-07-22 2023-06-16 山东绿叶制药有限公司 5-ht2a受体抑制剂或反向激动剂及其制备方法和应用
US20240208923A1 (en) 2021-03-10 2024-06-27 Jnana Therapeutics Inc. Small molecule inhibitors of mammalian slc6a19 function
CA3225133A1 (en) 2021-07-07 2023-01-12 Matthew Alexander James Duncton N,n-dimethyltryptamine and related psychedlics and uses thereof
EP4429672A4 (en) 2021-11-12 2025-04-30 Terran Biosciences Inc. PSILOCYBIN AND O-ACETYLPSILOCIN, SALTS AND SOLID FORMS THEREOF
WO2024123824A1 (en) * 2022-12-05 2024-06-13 Enveda Therapeutics, Inc. Nootkatone for the treatment of pruritus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070248690A1 (en) * 2006-04-24 2007-10-25 Trager Seymour F Composition and methods for alleviating symptoms of neurotoxicity
US20110281829A1 (en) * 2010-04-28 2011-11-17 Ipintl, Llc Novel composition
US20120183600A1 (en) * 2007-01-16 2012-07-19 Chien-Hung Chen Novel composition for treating metabolic syndrome and other conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US20070244202A1 (en) * 2004-06-28 2007-10-18 Kao Corporation Ampk Activator
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
CA2675638C (en) * 2007-01-16 2015-11-24 Ipintl, Llc Composition comprising serotonin for treating metabolic syndrome
WO2011112167A1 (en) * 2009-03-13 2011-09-15 Reset Therapeutics, Inc. Compositions and methods for diabetes treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070248690A1 (en) * 2006-04-24 2007-10-25 Trager Seymour F Composition and methods for alleviating symptoms of neurotoxicity
US20120183600A1 (en) * 2007-01-16 2012-07-19 Chien-Hung Chen Novel composition for treating metabolic syndrome and other conditions
US20110281829A1 (en) * 2010-04-28 2011-11-17 Ipintl, Llc Novel composition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
T.A.MAN’CHEVA: "Melatonin and Metformin inhibit skin carcinogenesis and lipid peroxidation induced by benz(a)pyrene in female mice", 《BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE》 *
VLADIMIR N. ANISIMOV等: "Metformin extends life span of HeR-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo", 《CELL CYCLE》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109689678A (zh) * 2016-09-20 2019-04-26 B·B·金 用于脂联素受体的激动剂肽
CN109689678B (zh) * 2016-09-20 2024-04-09 B·B·金 用于脂联素受体的激动剂肽
CN108159044A (zh) * 2018-02-26 2018-06-15 华中科技大学 抗坏血酸与二甲双胍的复合制剂用于制备化疗药物的应用
CN111960985A (zh) * 2018-08-08 2020-11-20 中国人民解放军总医院 抗肿瘤化合物
CN109771424A (zh) * 2019-03-11 2019-05-21 马慧 一种防治老年ⅱ型糖尿病性骨质疏松症的药物组合物及其应用
CN109793727A (zh) * 2019-03-13 2019-05-24 湖北科技学院 一种有效抗恶性肿瘤的药物组合物及其应用
US12612363B2 (en) 2019-06-19 2026-04-28 GH Research Ireland Limited Recrystallisation of 5-methoxy-N,N-dimethyltryptamine(5-MeO-DMT)
CN110559298A (zh) * 2019-10-28 2019-12-13 中国药科大学 一种天然化合物Egenine用于制备抗肾纤维化药物的用途

Also Published As

Publication number Publication date
AR095631A1 (es) 2015-10-28
EP2983473A2 (en) 2016-02-17
WO2014144130A3 (en) 2015-02-05
BR112015023922A2 (pt) 2017-07-18
TW201444552A (zh) 2014-12-01
IL241587B (en) 2019-01-31
AU2014227807A1 (en) 2015-11-05
AU2014227807B2 (en) 2018-03-08
KR20160005341A (ko) 2016-01-14
US20140350064A1 (en) 2014-11-27
CL2015002680A1 (es) 2016-09-02
WO2014144130A2 (en) 2014-09-18
HK1222297A1 (zh) 2017-06-30
EP2983473A4 (en) 2016-11-23
JP2016513734A (ja) 2016-05-16
RU2015143438A (ru) 2017-04-21
CA2909633A1 (en) 2014-09-18
MX2015012760A (es) 2016-06-17

Similar Documents

Publication Publication Date Title
AU2014227807B2 (en) Pharmaceutical composition comprising an AMPK activator and a serotonergic agent and methods of use thereof
US20120183600A1 (en) Novel composition for treating metabolic syndrome and other conditions
TWI556820B (zh) Ｈｓｐ９０抑制劑之組合
KR102427777B1 (ko) 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법
CN101415424B (zh) 用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合
CN104519887B (zh) 包含B‑Raf抑制剂、EGFR抑制剂和任选PI3Kα抑制剂的药物组合
JP2669507B2 (ja) 大脳卒中の治療のための薬剤
CN105579044A (zh) 双脱水半乳糖醇及其类似物与衍生物用于治疗复发性恶性神经胶瘤或进行性继发脑瘤的用途
JP2007533725A (ja) Ｃｒｔｈ２受容体アンタゴニストを用いたニューロパシー性疼痛処置方法
CN110461853A (zh) 苯并噻吩雌激素受体调节剂
KR20160037245A (ko) 과증식성 질환을 치료하기 위한 신규 조성물 및 방법
CN101466365A (zh) 增强认知功能的方法
CN115379835A (zh) 治疗冠状病毒的方法
CN118647379A (zh) 用于治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案
CN101495147B (zh) 药物组合
JP2017119702A (ja) ギラン・バレー症候群に伴う神経因性疼痛の予防又は治療剤
JP5681227B2 (ja) メチルフェニデート誘導体を含む治療剤及び医薬組成物
CZ20032341A3 (cs) Použití antagonistů GAL3 receptoru pro léčbu deprese a/nebo úzkosti
JP4429732B2 (ja) 癌の処置におけるグリベック（ｓｔｉ５７１）とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤
MX2008001971A (es) Combinacion de compuestos organicos.
CN114144179A (zh) 含血清素的试剂和5-ht1a受体拮抗剂
JP7130180B2 (ja) 子宮内膜症の処置のためのインドールの新規誘導体
WO2004014376A1 (en) Gal3 receptor antagonists for the treatment of affective disorders
CN1466587A (zh) 含有2-芳基-8-氧代二氢嘌呤衍生物作为活性成分的痴呆症治疗剂
HK40065810A (zh) 含血清素的试剂和5-ht1a受体拮抗剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160601

RJ01 Rejection of invention patent application after publication